Stock DNA
Pharmaceuticals & Biotechnology
DKK 130,596 Million ()
16.00
NA
0.00%
-0.88
27.45%
3.57
Revenue and Profits:
Net Sales:
6,085 Million
(Quarterly Results - Jun 2025)
Net Profit:
2,210 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
18.17%
0%
18.17%
6 Months
43.34%
0%
43.34%
1 Year
34.9%
0%
34.9%
2 Years
-6.1%
0%
-6.1%
3 Years
-37.08%
0%
-37.08%
4 Years
-16.08%
0%
-16.08%
5 Years
-11.99%
0%
-11.99%
Genmab A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
16.94%
EBIT Growth (5y)
3.02%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.61
Sales to Capital Employed (avg)
0.46
Tax Ratio
13.91%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
125.56%
ROE (avg)
18.85%
Valuation key factors
Factor
Value
P/E Ratio
16
Industry P/E
Price to Book Value
4.19
EV to EBIT
15.35
EV to EBITDA
15.35
EV to Capital Employed
8.00
EV to Sales
5.31
PEG Ratio
0.29
Dividend Yield
NA
ROCE (Latest)
52.10%
ROE (Latest)
25.96%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Jun 2025
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 5 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
6,084.60
5,402.00
12.64%
Operating Profit (PBDIT) excl Other Income
2,368.10
1,816.00
30.40%
Interest
59.20
19.00
211.58%
Exceptional Items
0.00
-176.00
100.00%
Consolidate Net Profit
2,210.20
1,408.00
56.97%
Operating Profit Margin (Excl OI)
389.20%
336.20%
5.30%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 12.64% vs 28.68% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 56.97% vs 3.76% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
21,526.00
16,474.00
30.67%
Operating Profit (PBDIT) excl Other Income
7,416.00
5,648.00
31.30%
Interest
120.00
27.00
344.44%
Exceptional Items
-300.00
0.00
Consolidate Net Profit
7,844.00
4,352.00
80.24%
Operating Profit Margin (Excl OI)
325.30%
323.00%
0.23%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 30.67% vs 13.57% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 80.24% vs -20.18% in Dec 2023
About Genmab A/S 
Genmab A/S
Pharmaceuticals & Biotechnology
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer, with a focus on solid tumors and hematological cancer. The Company has two approved antibodies: DARZALEX (daratumumab) and Arzerra (ofatumumab). DARZALEX is approved in combination with other standard therapies in frontline multiple myeloma, relapsed/refractory multiple myeloma and as a monotherapy for heavily pretreated or double-refractory multiple myeloma. It is marketed in the United States (U.S.), Europe and Japan. Arzerra is approved in certain territories for various chronic lymphocytic leukemia (CLL) indications and is marketed in the U.S. and Japan. The Company also develops a broad clinical and pre-clinical product pipeline, both own and partnered, and owns four proprietary antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Company Coordinates 
Company Details
Kalvebod Brygge 43 , KOEBENHAVN V None : 1560
Registrar Details






